Absci
18105 SE Mill Plain Blvd.
Vancouver
Washington
98683
United States
Tel: 360-949-1041
Email: people@absci.com
30 articles about Absci
-
In the latest example of big pharma entering AI collaborations or using AI-based tools, AstraZeneca’s deal with Absci will aim to produce an oncology candidate.
-
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
11/14/2023
Almirall S.A. and Absci Corporation announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
-
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
10/6/2021
EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced a discovery collaboration.
-
CerraCap Ventures portfolio company Totient acquired by Absci
7/9/2021
CerraCap Ventures, a leading early-stage Venture Fund, announced acquisition of its portfolio company Totient by Absci for an undisclosed amount.
-
Absci Strengthens Executive Leadership Team with Strategic Hires to Support Business Growth
7/7/2021
Absci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced two strategic hires joining its executive team: Nikhil Goel as Chief Business Officer and Dr. Sarah Korman as General Counsel.
-
Money on the Move: June 30 – July 6
7/7/2021
The long weekend didn't slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. -
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
-
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
6/16/2021
Viva Biotech declared that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics.
-
AbSci Announces Acquisition of Target Discovery Company Totient
6/14/2021
AbSci today announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets.
-
Money on the Move: March 17-23
3/24/2021
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week. -
AbSci Announces Acquisition of Deep Learning Company Denovium
1/12/2021
Integration of Denovium Engine™ with AbSci's Protein Printing™ Platform to enable creation of novel biotherapeutics and manufacturing cell lines with the click of a button
-
AbSci to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/7/2021
AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain , Founder and CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:25 a.m. PT / 10:25 a.m. ET .
-
AbSci Announces Recent Additions to Board of Directors
11/11/2020
AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing and discovery of biotherapeutics, today announced that Ivana Magovčević-Lie
-
AbSci Announces $65 Million Financing Led by Casdin Capital
10/20/2020
Financing to accelerate first mover advantage of Protein Printing™ technology which enables revolutionary efficiencies in protein manufacturing
-
AbSci CEO Sean McClain Named as an Entrepreneur Of The Year® 2020 Pacific Northwest Region Award Winner
10/15/2020
AbSci announced that Sean McClain, founder and CEO of AbSci, was named as an Entrepreneur Of The Year® 2020 Pacific Northwest Region Award winner.
-
AbSci Appoints Greg Schiffman As Chief Financial Officer
5/11/2020
AbSci, the Protein Printing™ company, is pleased to announce the appointment of Greg Schiffman, CPA as Chief Financial Officer.
-
AbSci Closes $15.4 M in Series D Funding to Accelerate Growth and Scale Disruptive Protein PrintingTM Technology, Announces Exclusive Co-Marketing Partnership with KBI Biopharma
1/13/2020
AbSci announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciences.
-
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
-
AbSci Develops Game-Changing 12-Week Cell Line Optimization Workflow and Adds Two New Members to Its Executive Team
4/5/2019
Martina Molsbergen, Vice President, Business Development and Johan Kers, PhD, Vice President, Research.